Showing results (1361-1370 of 1,717) with videos related to

Sort By:
Pageof 172
Leukemia|March 3, 2021
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trialRichard A Larson, Sumithra J Mandrekar, Lucas J Huebner, et al.
Blood Cancer Journal|March 27, 2024
How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?Ing Soo Tiong, Meaghan Wall, Ashish Bajel, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 7, 2020
Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18-45 years enrolled in a clinical trialL-H Wei, Y-Y Su, Y-M Hu, et al.
Blood|August 30, 2023
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLGSun Loo, Andrew W Roberts, Natasha S Anstee, et al.
Cancer Discovery|March 21, 2022
Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AMLJessica M Salmon, Izabela Todorovski, Kym L Stanley, et al.
Blood|February 1, 2023
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromesAmer M Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, et al.
Blood|April 7, 2021
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemiasRachel Thijssen, Sarah T Diepstraten, Donia Moujalled, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2024
Organ preservation after neoadjuvant long-course chemoradiotherapy versus short-course radiotherapyA Bercz, B K Park, E Pappou, et al.
Nature Cancer|February 5, 2022
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemiaClaudie Bosc, Estelle Saland, Aurélie Bousard, et al.
Blood|January 8, 2025
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AMLMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Pageof 172